Form 4 Tracker
Avalo Therapeutics, Inc.
AVTX

44 insider filings · Latest: Jun 23, 2026

Common Stock Transactions
Txn DateAcceptedInsiderTypeSharesAvg PriceValueShares OwnedFiling
Jun 23, 2026Jun 25 9:24 PMMittie DoyleChief Medical Officer
Sale
1,450$18.00$26.1K51,776(D)

View →

Jun 2, 2026Jun 2 8:08 PMJONATHAN GOLDMAN
Proposed Sale
42,833$14.39$616.2K

View →

May 28, 2026Jun 1 8:05 PMMittie DoyleChief Medical Officer
Sale
679$16.00$10.9K47,122(D)

View →

May 15, 2026May 19 8:10 PMMittie DoyleChief Medical Officer
Sale
3,000$18.76$56.3K3,622(D)

View →

May 7, 2026May 11 8:05 PMChristopher Ryan SullivanChief Financial Officer
Sale
18,606$24.12$448.8K423(D)

View →

May 7, 2026May 7 8:20 PMCHRISTOPHER SULLIVAN
Proposed Sale
18,606$21.81$405.8K

View →

May 6, 2026May 7 8:18 PMPaul VarkiChief Legal Officer
Sale
75,063$20.17$1.5M3,634(D)

View →

May 6, 2026May 7 8:16 PMChristopher Ryan SullivanChief Financial Officer
Sale
47,000$20.19$948.7K423(D)

View →

May 6, 2026May 7 8:16 PMMittie DoyleChief Medical Officer
Sale
106,555$20.68$2.2M3,622(D)

View →

May 5, 2026May 7 8:16 PMMittie DoyleChief Medical Officer
Sale
1,679$16.00$26.9K3,622(D)

View →

May 6, 2026May 7 8:15 PMMitchell ChanDirector
Sale
3,167$22.88$72.5K3,166(D)

View →

May 6, 2026May 6 8:54 PMMITTIE DOYLE
Proposed Sale
54,508$16.26$886.3K

View →

May 6, 2026May 6 8:32 PMCHRISTOPHER SULLIVAN
Proposed Sale
47,000$16.26$764.2K

View →

May 6, 2026May 6 8:30 PMPAUL VARKI
Proposed Sale
92,771$16.26$1.5M

View →

May 6, 2026May 6 8:29 PMMITCHELL CHAN
Proposed Sale
3,167$16.26$51.5K

View →

Apr 30, 2026May 1 8:37 PMChristopher Ryan SullivanChief Financial Officer
Sale
8,457$13.23$111.9K423(D)

View →

Apr 29, 2026May 1 8:37 PMChristopher Ryan SullivanChief Financial Officer
Sale
8,458$13.09$110.7K8,880(D)

View →

Apr 29, 2026Apr 29 8:33 PMCHRISTOPHER SULLIVAN
Proposed Sale
16,915$12.86$217.5K

View →

Apr 6, 2026Apr 8 8:51 PMMittie DoyleChief Medical Officer
Sale
3,970$18.01$71.5K3,622(D)

View →

Apr 6, 2026Apr 6 8:34 PMMITTIE DOYLE
Proposed Sale
65,800$17.76$1.2M

View →

Page 1 of 2

Next →

Stock Options & Derivatives
Txn DateAcceptedInsiderTypeSharesExercise PriceShares OwnedFiling
Mar 28, 2026Mar 31 8:12 PMAaron KantoffDirector
Option Exercise
3,1663,167(D)

View →

Mar 28, 2026Mar 31 8:12 PMGilla KaplanDirector
Option Exercise
3,1663,167(D)

View →

Mar 28, 2026Mar 31 8:11 PMGarry Arthur NeilDirector, Chief Executive Officer
Option Exercise
64,86664,867(D)

View →

Mar 28, 2026Mar 31 8:10 PMChristopher Ryan SullivanChief Financial Officer
Option Exercise
24,20024,200(D)

View →

Mar 28, 2026Mar 31 8:09 PMMitchell ChanDirector
Option Exercise
3,1663,167(D)

View →

Mar 28, 2026Mar 31 8:09 PMJonathan GoldmanDirector
Option Exercise
3,1663,167(D)

View →

Mar 16, 2026Mar 18 8:07 PMMittie DoyleChief Medical Officer
Option Exercise
25,492$12.65149,008(D)

View →

Feb 26, 2026Mar 2 9:24 PMPaul VarkiChief Legal Officer
Grant/Award
80,000$17.6480,000(D)

View →

Feb 26, 2026Mar 2 9:23 PMJennifer RileyChief Strategy Officer
Grant/Award
95,000$17.6495,000(D)

View →

Feb 26, 2026Mar 2 9:23 PMMittie DoyleChief Medical Officer
Grant/Award
105,000$17.64105,000(D)

View →

Feb 26, 2026Mar 2 9:22 PMTaylor BoydChief Business Officer
Grant/Award
95,000$17.6495,000(D)

View →

Feb 26, 2026Mar 2 9:22 PMChristopher Ryan SullivanChief Financial Officer
Grant/Award
105,000$17.64105,000(D)

View →

Feb 26, 2026Mar 2 9:20 PMGarry Arthur NeilDirector, Chief Executive Officer
Grant/Award
286,000$17.64286,000(D)

View →

← Previous

Page 2 of 2